The interim report is set for release at 8:00 a.m. CEST on the same day. During the afternoon briefing, CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson will outline the company's performance. Participants can join the presentation via a dedicated webcast portal or register for the teleconference to receive dial-in credentials.

Implantica, currently listed on the Nasdaq First North Premier Growth Market in Stockholm, centers its operations on advanced implantable technologies. The company’s primary focus remains its CE-marked RefluxStop device, designed to treat gastroesophageal reflux disease. Beyond this, the firm maintains a pipeline involving eHealth remote monitoring and wireless energy platforms intended to power implants through intact skin.